Prevention of recurrent lower urinary tract infections in postmenopausal women with genitourinary syndrome: outcome after 6 months of treatment with ospemifene

References

• Pinkerton JV, Kagan R. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use. Expert Opin Pharmacother 2015;16:2703–14.
   PubMed Web of Science ®Google Scholar
• Palacios S, Cancelo MJ. Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy. Int J Womens Health 2016;8:617–26.
   PubMed Web of Science ®Google Scholar
• Marrai R, Lissi G, Togni S, et al. Efficacy and tolerability of a plant-based multicomponent cream (Ginetrox) in vulvo vaginal disorders of the genitourinary syndrome during menopause. Minerva Ginecol 2017;69:245–9.
   PubMed Web of Science ®Google Scholar
• Perrotta C, Aznar M, Mejia R, et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev 2008;(2):CD005131.
   PubMed Web of Science ®Google Scholar
• Lüthje P, Brauner H, Ramos NL, et al. Estrogen supports urothelial defense mechanisms. Sci Transl Med 2013;5:190ra80.
   PubMed Web of Science ®Google Scholar
• Dueñas-Garcia OF, Sullivan G, Hall C. Pharmacological agents to decrease new episodes of recurrent lower urinary tract infections in postmenopausal women. A systematic review. Female Pelvic Med Reconstr Surg 2016;22:63–9.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Particco M, Biglia N, et al. Attitudes and perceptions towards vulvar and vaginal atrophy in Italian post-menopausal women: evidence from the European REVIVE survey. Maturitas 2016;91:74–80.
   PubMed Web of Science ®Google Scholar
• Hickling DR, Nitti VW. Management of recurrent urinary tract infections in healthy adult women. Rev Urol 2013;15:41–8.
   PubMedGoogle Scholar
• Ahmed H, Davies F, Francis N, et al. Long term antibiotics for prevention of recurrent urinary tract infection in older adults: systematic review and meta-analysis of randomised trials. BMJ Open 2017;7:e015233.
   PubMed Web of Science ®Google Scholar
• Boyle DP, Zembower TR. Epidemiology and management of emerging drug-resistant gram-negative bacteria: extended-spectrum β-lactamases and beyond. Urol Clin North Am 2015;42:493–505.
   PubMed Web of Science ®Google Scholar
• Del Pup L. Ospemifene: a safe treatment of vaginal atrophy. Eur Rev Med Pharmacol Sci 2016;20:3934–44.
   PubMed Web of Science ®Google Scholar
• Benagiano G, Bastianelli C, Farris M, Brosens I. Selective progesterone receptor modulators: an update. Expert Opin Pharmacother 2014;15:1403–15.
   PubMed Web of Science ®Google Scholar
• Parsons CL, Dell J, Stanford EJ, et al. Increased prevalence of interstitial cystitis: previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravescical potassium sensitivity. Urology 2002;60:573–8.
   PubMed Web of Science ®Google Scholar
• Burholt V, Nash P. Short form 36 (SF-36) health survey questionnaire: normative data for Wales. J Public Health (Oxf) 2011;33:587–603.
   PubMed Web of Science ®Google Scholar
• Clayson D, Wild D, Doll H, et al. Validation of a patient-administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in uncomplicated urinary tract infection (UTI): the UTI symptom assessment questionnaire. BJU Int 2005;96:350–9.
   PubMed Web of Science ®Google Scholar
• Bachman G. Urogenital ageing: an old problem newly recognized. Maturitas 1995;(22 Suppl.):S1–S5.
   PubMed Web of Science ®Google Scholar
• Najar MS, Saldanha CL, Banday KA, et al. Approach to urinary tract infections. Indian J Nephrol 2009;19:129–39.
   PubMedGoogle Scholar
• Steinert T, Eisele F, Langle G, et al. [PGI-I (patient’s global impression) as an outcome and quality indicator psychiatric in-patient treatment: results and concordance with doctor’s assessments]. Psychiatr Prax 2010;37:343–9.
   PubMed Web of Science ®Google Scholar
• Caretto M, Giannini A, Russo E, et al. Preventing urinary tract infections after menopause without antibiotics. Maturitas 2017;99:43–6.
   PubMed Web of Science ®Google Scholar
• Grabe M, Bartoletti R, Bjerklund Johansen TE, et al. Guidelines on urological infections. Eur Assoc Urol 2015. Available from: https://uroweb.org/wp-content/uploads/19 Urological-infections_LR2.pdf. [Last accessed 23 Aug 2017].
   PubMedGoogle Scholar
• Raz R. Urinary tract infection in postmenopausal women. Korean J Urol 2011;52:801–8.
   PubMedGoogle Scholar
• Minkin MJ, Maamari R, Reiter S, et al. Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy. Int J Womens Health 2013;5:133–9.
   PubMedGoogle Scholar
• Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol 2014;32:79–84.
   PubMed Web of Science ®Google Scholar
• Torella M, Del Deo F, Grimaldi A, et al. Efficacy of an orally administered combination of hyaluronic acid, chondroitin sulfate, curcumin and quercetin for the prevention of recurrent urinary tract infections in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2016;207:125–8.
   PubMed Web of Science ®Google Scholar
• Ciani O, Arendsen E, Romancik M, et al. Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study. BMJ Open 2016;6:e009669.
   PubMed Web of Science ®Google Scholar
• Cervigni M, Sommariva M, Tenaglia R, et al. A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis. Neurourol Urodyn 2017;36:1178–86.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Perniola G, Di Donato V, et al. Severe pelvic organ prolapse treated by vaginal native tissue repair: long-term analysis of outcomes in 146 patients. Arch Gynecol Obstet 2017;295:917–22.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Zullo MA, Faiano P, et al. Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms. Gynecol Endocrinol 2017:1-4. doi:10.1080/09513590.2017.1323859
   PubMed Web of Science ®Google Scholar